Roche and Nurix Partner on BTK Degrader Bexobrutideg for Blood Cancers
Roche partners with Nurix on BTK degrader bexobrutideg for blood cancers, paying $700M upfront and splitting U.S. profits equally...
No videos found.
The Biased GLP-1 Signal: Ecnoglutide’s 35% Edge Over Semaglutide Is the Opening Shot in Obesity’s Next Competitive War
Sciwind's ecnoglutide beat semaglutide by 35% on weight loss in a head-to-head trial—and it signals a coming wave of...
DaltonTx launches drug discovery platform with Sygnature Discovery
DaltonTx launches drug discovery platform with Sygnature Discovery to preserve medicinal chemistry decisions and reduce synthesis cycles.
BeyondSpring Replaces Founder as CEO Ahead of Plinabulin DUBLIN-4 Trial
BeyondSpring replaces founder as CEO ahead of the Plinabulin DUBLIN-4 Trial, its confirmatory Phase 3 study in NSCLC.
Drew Brees Partners With ARS Pharmaceuticals on Neffy Awareness Campaign
Drew Brees partners with ARS Pharmaceuticals to promote Neffy, a needle-free nasal spray for anaphylaxis approved by the FDA...
Scilex to Distribute 14 Million Semnur Shares on June 15, 2026
Scilex distributes 14 million Semnur Shares on June 15, 2026, retaining control of the sciatica-focused biotech behind Phase 3-validated...
Novo Nordisk’s Zenagamtide Isn’t Chasing Ozempic — It’s Trying to Make Tirzepatide Obsolete
Novo Nordisk's zenagamtide hit 14.6% weight loss and 89.1% A1C control in Phase 2. Here's what the ADA 2026...
ResMed Acquires Noctrix Health for $340 Million in Angelini Ventures’ First Exit
ResMed acquires Noctrix Health for $340 million, gaining FDA-cleared Nidra wearable device for restless leg syndrome treatment.
Stipple Bio Licenses Lonza ADC Technology for Multi-Target Oncology Pipeline
Stipple Bio licenses Lonza ADC technology for multi-target oncology pipeline, securing manufacturing partnership before clinical trials begin in 2027.
mRNA 2.0 Is Not a Science Story — It’s a $31 Billion Platform Bet That Most Pipelines Aren’t Priced For
Nature Reviews Drug Discovery maps mRNA's expansion into enzyme replacement and cancer immunotherapy—here's what it means for pipeline valuations...